Compare · AIMD vs NVO
AIMD vs NVO
Side-by-side comparison of Ainos Inc. (AIMD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 12033.3x AIMD ($16.3M).
- Over the past year, AIMD is down 26.2% and NVO is down 43.0% - AIMD leads by 16.9 points.
- AIMD has been more active in the news (12 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Ainos Inc.
- Novo Nordisk A/S
- Price
- $1.92-2.04%
- $43.88-0.20%
- Market cap
- $16.3M
- $195.92B
- 1M return
- +11.63%
- -6.80%
- 1Y return
- -26.15%
- -43.03%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 3
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AIMD
- Director Chiang Yao-Chung bought $7,175 worth of shares (3,500 units at $2.05) (SEC Form 4)
- Ainos Releases 2026 Mid-Year CEO Letter to Shareholders
- Director Chiang Yao-Chung bought $4,260 worth of shares (2,000 units at $2.13) (SEC Form 4)
- VASRO Research Highlights Ainos Smell AI Expansion into Emergency Department Operations
- Zacks SCR Discusses Ainos' Expansion of Smell AI into Healthcare Infrastructure Through NTUH Study
- Director Chiang Yao-Chung bought $575 worth of shares (250 units at $2.30) (SEC Form 4)
- Ainos Launches Smell AI Study at National Taiwan University Hospital for ER Overcrowding and Respiratory Infection Risk Analysis
- Director Chiang Yao-Chung bought $4,000 worth of shares (2,000 units at $2.00) (SEC Form 4)
- Director Lee Ting-Chuan sold $208,977 worth of shares (109,988 units at $1.90), decreasing direct ownership by 12% to 807,417 units (SEC Form 4) to satisfy tax liability
- Large owner Taiwan Carbon Nano Technology Corp sold $96,760 worth of shares (41,000 units at $2.36), decreasing direct ownership by 4% to 948,925 units (SEC Form 4) (withholding obligation)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care